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Chronic obstructive pulmonary disease (COPD) is characterized by the abnormal and chronic lung inﬂammation. We hypoth-
esized that lung ﬁbroblasts could contribute to the local inﬂammation and investigated whether low dose theophylline had a
beneﬁcial eﬀect on ﬁbroblasts inﬂammation. Subjects undergoing lobectomy for bronchial carcinoma were enrolled and divided
into COPD and control groups according to spirometry. Primary human lung ﬁbroblasts were cultured from peripheral lung
tissue distant to tumor tissue. There was a signiﬁcant increase in both the mRNA expressions and protein levels for IL-6 and IL-8
in ﬁbroblasts in COPD group, and the values were negatively correlated with lung function (P<0.05). For COPD ﬁbroblasts,
the protein levels of IL-6 and IL-8 decreased from 993.0 ± 738.9pg/mL to 650.1 ± 421.9pg/mL (P = 0.014) and from 703.1 ±
278.0pg/mL to 492.0 ± 214.9pg/mL (P = 0.001), respectively, with 5μg/mL theophylline treatment. In addition, theophylline at
thedoseof5μg/mLreducedtheincreasedproductionofIL-6andIL-8inducedby1μg/mLLPSinprimaryhumanlungﬁbroblasts.
Our data suggest that lung ﬁbroblasts participate in the chronic inﬂammation in COPD by releasing IL-6 and IL-8, and low dose
theophylline can alleviate the proinﬂammatory mediators’ production by ﬁbroblasts.
1.Introduction
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality worldwide
and results in an economic and social burden that is both
substantial and increasing [1]. It is currently the ﬁfth
leading cause of mortality worldwide and is predicted to
become the third most common cause of death worldwide
by 2030 [2]. COPD is characterized by the abnormal and
chronic inﬂammation induced by cigarette smoking and
otherinﬂammatoryinsultsinbothsmallairwayandlungpa-
renchyma [3, 4].
Human lung ﬁbroblasts are major structural cells orches-
trating repair and remodeling in COPD. It is well acknowl-
edged that the dysfunction of lung ﬁbroblasts is partially
responsible for small airway remodeling and peripheral em-
physema in the progression of COPD [5, 6]. From another
perspective, ﬁbroblasts are gradually believed to be involved
in the inﬂammatory process in the lung along with neu-
trophils, macrophages, T cells, and epithelial cells [7]. Data
from recent studies have demonstrated that lung ﬁbroblasts
participate in the inﬂammation in response to diesel exhaust
particles [8] and in asthma patients [9]. We therefore
hypothesized that lung ﬁbroblasts contribute to the chronic
inﬂammation in the development of COPD. Our previous
data showed that ﬁbroblasts explanted from human distal
lungtissuesecretedhigherlevelsofinterleukin(IL)-6andIL-
8 in response to lipopolysaccharide (LPS) in vitro, while the
productions of tumor necrosis factor (TNF)-α, IL-12p70, IL-
1β, and IL-10 were at low levels or not altered [10]. We thus
assumed that pulmonary ﬁbroblasts in patients with COPD
could participate in the local inﬂammation by producing a
higher level of IL-6 and IL-8.
The control of the abnormal chronic local inﬂammation
is regarded as a key strategy for managing COPD; how-
ever, with the relative glucocorticoids (GCs) insensitivity in2 Mediators of Inﬂammation
COPD, there remain no eﬀective anti-inﬂammatory treat-
ments [11–13]. The alternative anti-inﬂammatory treat-
ments which are currently available include low dose the-
ophylline [14–16]. Theophylline is often described as a
phosphodiesterase (PDE) inhibitor, but the concentrations
that can achieve the anti-inﬂammatory eﬀect are below the
concentrationatwhichittargetsPDEandthereforeavoidthe
side eﬀect under high dose [17]. Clinical research in COPD
showed that theophylline at the dose of 400mg/day reduced
both neutrophils counts and the levels of neutrophil elastase,
myeloperoxidase, IL-8, and TNF-α in sputum [16, 17]. It
is uncertain whether low dose theophylline would have a
beneﬁcial eﬀect on ﬁbroblasts inﬂammation. The purpose of
this study was to address these issues in primary human lung
ﬁbroblasts explanted and cultured from subjects with COPD
and non-COPD controls.
2. Methods
2.1.Subjects. Primary ﬁbroblastswere culturedfromperiph-
eral lung tissue obtained at surgery for bronchial carcinoma.
Patients were prospectively enrolled between October 2009
and February 2010. The demographic data including age,
gender, smoking history, and past medical history were
documented, and spirometry was performed preoperatively.
Patients with clearly documented history of other lung
diseases such as asthma, bronchiectasis, and interstitial lung
disease were excluded. According to the classiﬁcation of
severity of COPD from Initiative for Chronic Obstructive
Lung Disease (GOLD) 2009 [1], patients were divided into
COPD group and control group (Table 1). The consecutive
eight specimens from December 2009 to February 2010 were
usedforLPStreatmentexperiments.Thestudywasapproved
by the Ethic Committee of Zhongshan Hospital of Fudan
University where samples were collected, and it was regis-
tered at Chinese Clinical Trial Registry (no. ChiCTR-OCC-
00000781). Written informed consent for the acquisition of
material for research was obtained preoperatively.
2.2. Isolation and Cultures of Human Lung Fibroblasts. Hu-
man lung ﬁbroblasts were isolated from surgical specimens
of distant lesion-free and pleura-free lung tissue. Sam-
ples were immediately transferred into complete medium
(Dulbecco’s modiﬁed Eagle’s medium (DMEM), 10% fetal
calf serum (FCS), penicillin (100ng/mL), and streptomycin
(100ng/mL)) (Invitrogen). The tissue was minced with
a scalpel (1-2mm2) and transferred into 25cm2 culture
dishes for primary culture at 37◦Ci n5 %C O 2.C e l l sw e r e
trypsinised when they were conﬂuent and then passaged at
a 1:3 ratio. Puriﬁed human lung ﬁbroblasts cells of passage
3 were seeded at a density of 50000cells/well in 12 well
plates and were grown in 1mL complete medium for 24h.
Thencell-freesupernatantswerecollectedandtotalRNAwas
extracted for further experiments.
To conﬁrm the purity of the cultured ﬁbroblasts, the
recovered cells were identiﬁed by their morphology, adher-
ent nature, expression of vimentin (ﬁbroblast marker)
and lack of expression of cytokeratin (epithelial marker),
Table 1: Clinical and demographic features of the subjects.
COPD† Control‡ P value
Gender (M/F) 5/5 5/3 NS
Age (yrs) 65.3 ±9.86 9 .5 ±3.1N S
Smoking history (pack-yrs) 43.0 ±17.73 0 .0 ±10.0N S
FEV1 (L) 1.35 ±0.26 2.20 ±0.33 <0.001
FEV1% pred 68.7 ±18.79 0 .2 ±5.5 0.0128
FVC (L) 2.75 ±0.76 2.97 ±0.45 NS
FVC% pred 86.2 ±20.58 9 .0 ±10.2N S
FEV1/FVC% 57.4 ±8.87 9 .3 ±9.4 <0.001
Data are presented as mean ± SD. COPD: chronic obstructive pulmonary
disease; M: male; F: female; FEV1: forced expiratory volume in one second;
% pred: % predicted; FVC: forced vital capacity; NS: nonsigniﬁcant.
†Subjects having an FEV1/FVC < 70%. ‡Subjects having an FEV1/FVC ≥
70%.
vonWillebrand factor (endothelial markers), and SM22
( s m o o t hm u s c l em a r k e r ) .
2.3. ELISA. OptEIA ELISA kits for human interleukin (IL)-6
and IL-8 were purchased from BD. The level of protein of
interest in cell-free culture supernatants was determined ac-
cording to the manufacturer’s instructions.
2.4. Real Time RT-PCR. Total RNA extraction was per-
formed using Trizol Reagent (Invitrogen Life Technologies),
andthen1μgoftotalRNAwastranscribedusingSuperScript
ViLOTM cDNA synthesis kit (Invitrogen Life Technologies)
according to the manufacturer’s instructions.
Real-time PCR was performed using Express SyBR
GreenERTM SuperMix with Premixed ROX (Invitrogen
LifeTechnologies)followingthemanufacturer’sinstructions.
Thefollowingprimerswereused:IL-6forward,5
 -TACCCC
CA GGA GAA GA TTCC-3  ;IL -6r ev erse,5  -GCCATCTTT
GGA AGG TTC AG -3 ;I L - 8f o r w a r d ,5  -TCT GCA GCT
CTG TGT GAA GGT GCA GTT -3 ;I L - 8r e v e r s e ,5  -A A C
CCT CTG CAC CCA GTT TTC CT -3 ; GAPDH forward,
5 -TGA GCA CCA GAT TGT CTC CT -3 ; GAPDH reverse,
5 -G C AT C AA A GG T GG A AG A CT G- 3  . PCR assays
were performed in duplicate on the 7900HT real-time PCR
machine (Applied Biosystems), and the cycler conditions
were as follows: incubation for 2min at 50◦C followed by
anotherincubationstepat95◦Cfor10min,afterwards15sat
95◦Cand1minat60◦Cfor40cycles.Reactionspeciﬁcitywas
evaluated by melting curve analysis which was performed
by heating the plate from 55 to 95◦C and measuring SYBR
Green I dissociation from the amplicons. The calculation of
threshold cycles (Ct values) and further analysis of these
data were performed by the Sequence Detector software. The
relative expression of HDAC2 mRNA in each sample was
quantiﬁed and normalized to the GAPDH mRNA levels by
the 2−ddCt method [18].
2.5. In Vitro Treatments. Passage 3 cells were seeded as men-
tioned before and then cultured in complete medium with or
without 5μg/mL theophylline for 48h, followed by collect-
ing supernatants and measuring IL-6 or IL-8. To evaluateMediators of Inﬂammation 3
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Figure 1: Increased mRNA expression and protein production of interleukin-6 (IL-6) in lung ﬁbroblasts from COPD patients. (a) Real-
time RT-PCR was adopted to evaluate the transcription levels of IL-6, and the relative expression was calculated based on the expression of
GAPDH. ∗∗∗P<0.001, when compared to control group. (b) The relationship of IL-6 mRNA expression and FEV1. (c) The protein level of
IL-6. ELISA was used to measure the concentration of IL-6 in the cell-free supernatants. ∗P<0.05, when compared to control group. (d)
The relationship of IL-6 secretion and FEV1.
the eﬀect theophylline on the production of cytokines in-
duced by LPS, puriﬁed human lung ﬁbroblasts were grown
in a complete medium (5% CO2 at 37◦C) for 24h. Sub-
sequently, the human lung ﬁbroblasts were treated with
1μg/mL LPS (Escherichia coli serotype 0111:B4, Sigma) for
48h in the presence or absence of 5μg/mL theophylline, and
t h e nc e l lf r e es u p e r n a t a n t sw e r ec o l l e c t e df o rl a t e ra n a l y s i s .
2.6. Statistics. All statistical analysis was performed using
GraphPadPrism 5.0 for Windows. D’Agostino and Pearson
omnibus normality test was performed at ﬁrst. If data were
normally distributed, they were expressed as mean ± SD,
and t-tests or repeated measures test of ANOVA followed
by Dunnett’s post-test were performed to calculate statistical
diﬀerences between two groups or among three groups,
respectively. Otherwise, data were expressed as median with
interquartile range, and comparisons were made by Mann
Whitney test between two groups. Correlation analysis was
done by Spearman or Pearson test for normally or abnor-
mally distributed data, respectively. Diﬀerences were consid-
ered signiﬁcant at the level of P<0.05.
3. Results
3.1.ClinicalandDemographicFeaturesoftheSubjects. Totally
18subjectswereenrolledintothecurrentstudyandclassiﬁed4 Mediators of Inﬂammation
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Figure 2: Increased mRNA and protein levels of interleukin-8 (IL-8) in lung ﬁbroblasts from COPD patients. (a) Real-time RT-PCR was
adopted to evaluate the transcription levels of IL-8, and the relative expression was calculated based on the expression of GAPDH. ∗∗P =
0.002, when compared to control group. (b) The relationship of IL-8 mRNA and FEV1. (c) The protein level of IL-8 of primary lung
ﬁbroblasts from subjects with COPD. ELISA was adopted to measure the concentration of IL-8 in the cell-free supernatants. ∗∗∗P<0.001,
when compared to control group. (d) The relationship of IL-8 secretion.
as COPD or control group according to GOLD 2009 [1].
The two groups were similar in age, gender, and smoking
status (Table 1). The two groups diﬀered signiﬁcantly in lung
function.Asexpected,thesubjectsinCOPDgrouphadlower
FEV1% predicted and FEV1/FVC%, with values as 68.9 ±
18.7% versus 90.2±5.5% (P = 0.013) and 57.4±8.8% versus
79.3 ±9.4% (P<0.001), respectively.
3.2. A Signiﬁcant Higher mRNA and Protein Level for IL-
6 and IL-8 in Fibroblasts from Subjects with COPD. The
primary cultured cells from human lung tissue appeared to
have typical morphology of ﬁbroblast, and immunostaining
showed that >99% of the cells were vimentin positive. Stain-
ing with antibodies to cytokeratin, von Willebrand factor,
and SM22 was negative, indicating that the cultures did not
contain signiﬁcant numbers of epithelial or mesothelial cells,
endothelial cells, or smooth muscle cells.
There was a signiﬁcant increase in the expression of
mRNA for IL-6 (Figure 1(a)) and IL-8 (Figure 2(a))f o r
ﬁbroblasts in COPD group. In addition protein levels were
increased in the supernatants from the ﬁbroblasts in COPD
group compared with control group for IL-6 ((993.0 ±
738.9)pg/mL versus (241.5 ± 148.4)pg/mL, P = 0.012,
Figure 1(c)) and for IL-8 ((703.1 ± 278.0)pg/mL versus
(165.0 ± 77.5)pg/mL, P<0.001, Figure 2(c)). As shown
in Figures 1 and 2, the mRNA expression and protein
production of IL-6 and IL-8 of ﬁbroblasts from individual
subject were negatively correlated with FEV1 (P<0.05).Mediators of Inﬂammation 5
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Figure 3: Low dose theophylline (5μg/mL) inhibited the production of interleukin-6/-8 in lung ﬁbroblasts from COPD patients. Data
were obtained from 10 independent cell lines. ∗P<0.05, and ∗∗P<0.01, when results between diﬀerent treatments were compared. IL:
interleukin; Theo: theophylline.
3.3.LowDoseTheophyllineInhibitedIL-6andIL-8Production
of Human Lung Fibroblasts Isolated from Subjects with COPD.
Theophylline at the concentration of 5μg/mL showed an
inhibitory eﬀect on the production of IL-6 and IL-8 in
ﬁbroblasts cultured from COPD patients. The levels of IL-6
and IL-8 decreased to (650.1 ± 421.9)pg/mL (P = 0.014,
Figure 3(a)) and to (492.0±214.9)pg/mL (P = 0.001, Figure
3(b)), respectively. No eﬀect of theophylline on the cytokine
production by control cells was observed. The treatment of
theophylline had no eﬀect on cell proliferation and viability
(data not shown).
3.4. Low Dose Theophylline Partly Blocked the LPS-Induced
IL-6 and IL-8 Secretion from Human Lung Fibroblasts. To
evaluate whether LPS was aﬀecting the production of IL-6
and IL-8 from primary human lung ﬁbroblast, the cells
were treated with or without 1μg/mL LPS. The dose of LPS
was adopted based on our previous concentration-response
experiments [10]. As shown in Figure 4, in response to 24-
hour incubation of 1μg/mL LPS, the concentration of IL-6
in the supernatants of cultured ﬁbroblasts was signiﬁcantly
increased from 1150 ±426pg/mL to 1559 ±406pg/mL (P<
0.05). A similar increase from 560 ± 205pg/mL to 1087 ±
359pg/mL was observed for IL-8 (P<0.05). The treatment
of theophylline at the dose of 5μg/mL partly blocked the
signiﬁcant increase induced by LPS.
4. Discussion
Chronic inﬂammation of the small airway and surrounding
lung parenchyma involving a variety of cells and inﬂamma-
tory mediators is presumably of major importance in the
development and progression of COPD [3, 4]. Most of the
previous studies have focused on the role of macrophages,
neutrophils, and epithelial cells in the pathophysiology of the
disease. In the current study, we found that compared with
the control group with normal lung function, primary lung
ﬁbroblasts from subjects with COPD produced higher levels
of IL-6 and IL-8 which were reduced by theophylline in vitro.
The increased levels of IL-6 or IL-8 we found in
primary pulmonary ﬁbroblasts from COPD patients were
similar to those reported in sputum [19], exhaled breath
condensate [20], and blood [21]. IL-6 is regarded to act
as a proinﬂammatory cytokine and is also associated with
epithelialapoptosisandinjuryinCOPD[22].IL-8isapotent
attractant for neutrophils and has been demonstrated to be
responsible for the acute exacerbation and disease progres-
sion of COPD [19, 20]. Studies examining the circulation
levels of IL-6 or IL-8 in COPD patients have suggested
that inﬂammatory cells such as alveolar macrophages or
epithelial cells are major sources of IL-6 or IL-8 [23–25].
However, Rao et al. [26] showed in a rat model that it is
lung ﬁbroblasts rather than alveolar macrophages that act
as a signiﬁcant source of IL-6. Ward et al. [9] showed that
cultured myoﬁbroblasts from asthma patients produced a
higherlevelofIL-8inthepresenceofIL-1.Recentresearchby
He et al. [27] conﬁrmed the expression of Toll-like receptors
and its downstream signal transduction in lung ﬁbroblasts,
indicating that lung ﬁbroblasts are also important target
cells directly inﬂuenced by inﬂammatory stimuli. In the
current study, we also observed the increased IL-6 and IL-8
productionbyprimaryhumanlungﬁbroblastsinresponseto
LPS,apotentandubiquitousproinﬂammatoryagent.Taking
these ﬁndings together, we can safely conclude that lung
ﬁbroblasts are at least one of the sources of IL-6 and IL-8 and
contribute to the ongoing inﬂammation in COPD.
It is notable that theophylline at the dose of 5μg/mL
reduced the in vitro IL-6 and IL-8 release by lung ﬁbroblasts
isolated from COPD patients or partly blocked the LPS-
induced cytokines release. These results are consistent with
the ﬁndings in clinical research and in vitro macrophage
cultures[17,28].Iiboshietal.[17]showedthatfourweeksof
theophyllinetreatmentreducedIL-8levelinsputumofstable6 Mediators of Inﬂammation
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Figure 4: The eﬀect of theophylline on the lipopolysaccharide-
induced cytokine production in primary human lung ﬁbroblasts.
Data were obtained from 8 independent cell lines. The cells were
cultured for 48h at the absence or presence of 1μg/mL LPS, and the
eﬀect of theophylline at the concentration of 5μg/mL was analyzed.
The production of IL-6 (a) and IL-8 (b) was quantitated by ELISA.
The results were expressed as mean±SD in picograms per milliliter.
P<0.05, when statistics were performed among −LPS/−Theo,
+LPS/−Theo, and +LPS/+Theo. ∗P<0.05, ∗∗P<0.01, and
∗∗∗P<0.001, when results between two diﬀerent treatments
were compared. LPS: lipopolysaccharide; IL: interleukin; Theo:
theophylline.
COPD.LevelsofIL-8releasedbyLPS-stimulatedTHP-1cells
and neutrophils were reduced by treatment with 10μg/mL
theophylline [17]. A recent study also showed that low dose
theophylline led to an additional reduction in sputum IL-8
and increase in total histone deacetylase (HDAC) activity in
peripheral blood monocytes and neutrophils [28]. GCs are
currently the most eﬀective anti-inﬂammatory therapy for
COPD;however,ithasbeenconﬁrmedthatposttranslational
modiﬁcations of glucocorticoid receptors (GRs), as well as
decreased expression and activity of HDAC2, lead to the GCs
resistance in patients with COPD [29]. Considering the
relative GC-insensitivity in COPD, it is reasonable to use
low dose theophylline as an available alternative or add-on
anti-inﬂammatory therapy for COPD patients [14, 28, 29].
Importantly, lung ﬁbroblasts are responsible for the extracel-
lular matrix regeneration and maintenance, and GCs would
interfere with cell proliferation and impair the tissue repair
capacity of ﬁbroblasts. Therefore, low dose theophylline
might be more appropriate than GCs for inhibiting the in-
ﬂammation in COPD ﬁbroblasts.
The exact mechanism of the anti-inﬂammatory eﬀect
of low-dose theophylline is not thoroughly known. It is
assumedtobeassociatedwiththerestorationofHDACactiv-
ity [30, 31]. HDAC suppresses inﬂammatory gene expression
and appears to be the key regulator in the development and
procession of COPD [32, 33]. The HDAC activity was found
to be reduced in alveolar macrophage of COPD patients
[34]. It was reported by Cosio et al. [30] that theophylline
induced a six-fold increase in HDAC activity in COPD
alveolar macrophage lysates and signiﬁcantly enhanced
dexamethasone suppression of induced IL-8 release. The
mechanism underlying the inhibitory eﬀect of theophylline
on the cytokine release in COPD lung ﬁbroblasts is required
to be further investigated.
In summary, these data provided novel and direct
evidences supporting the idea that lung ﬁbroblasts partic-
ipate in the abnormal inﬂammation in COPD. Low dose
theophylline can reduce the release of proinﬂammatory
mediators by ﬁbroblasts, which would fortify the scientiﬁc
rationale for its clinical use.
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